Bayer Financial News

Companies growing more comfortable with artificial intelligence are bringing the latest tools into their supply chains, with goals of cutting costs, speeding up distribution and getting ahead of potential disruptions. The early steps suggest areas where logistics operators see the greatest near-term benefits from generative AI, the developing technology tool that can quickly sort through large amounts of information, make predictions and respond to questions in a humanlike voice.

Biocon Biologics on Monday said it has inked a patent settlement agreement with Bayer Inc and Regeneron Pharmaceuticals Inc, paving the way for it to launch a biosimilar product in Canada. The settlement pact paves the way for the introduction of Yesafili, a proposed biosimilar to Eeylea (aflibercept) injection, in the Canadian market, Biocon Biologics said in a regulatory filing. Under the terms of the agreement, Biocon Biologics has secured a launch date for the product no later than July 1, 2025, it added.

A Delaware judge has declared a mistrial in the latest lawsuit alleging that exposure to the popular weedkiller Roundup causes cancer

Edelweiss Alternatives, the alternative asset arm of the Edelweiss Group, has finalised a deal to acquire MFAR Developers’ 1.21-million-sq-ft information technology park in Bengaluru for over Rs 1,475 crore, said multiple persons with direct knowledge of the development. This is the largest and first transaction for a complete buyout of an office tower so far this year. Edelweiss Alternatives is buying this asset through its rental fund, which is currently in the process of raising Rs 5,000 crore. The 12-storey office tower, which is in north Bengaluru’s Hebbal locality along Bellary Road and Outer Ring Road (ORR), is an independent asset within an ecosystem of large integrated mixed-use development.

FRANKFURT (Reuters) — Germany's Bayer (OTC:BAYRY) said on Monday that it was amending its dividend policy to pay the legal minimum for a period of three years to reduce debt in a decision it said it did not take lightly.

The Bayer Corporation has spent more than $10 billion to settle lawsuits that claim the popular weed killer Roundup causes cancer

recently certified class action lawsuit is seeking at least $1.2 billion from multinational company Bayer on behalf of Canadians who claim to have been harmed while using Roundup weedkiller products.The allegations have not yet been tested in court and Bayer says it stands behind the safety of the products.Roundup, the brand name of a glyphosate-based herbicide that is the subject of the lawsuit, is the most commonly used herbicide in the world and has been sold across Canada since 1976 by U.S. company Monsanto. The German pharmaceutical giant Bayer acquired Monsanto in 2018.About 165,000 claims have been filed in the U.S.

(Reuters) -Regeneron Pharmaceuticals on Monday reported eye drug Eylea's fourth-quarter preliminary U.S. sales below Wall Street expectations, as the company's blockbuster product faced pressure from a rival.

European shares were marginally higher on Wednesday as robust China data lifted miners, while an overnight Wall Street rally amid persisting optimism the Federal Reserve could begin cutting rates as early as next March helped tech stocks rise. By 0814 GMT, the pan European STOXX 600 rose 0.1% at 477.83 points following an over 0.4% gain across major Wall Street indexes overnight. Basic resources was amongst the top gainers, rising 0.4% as most base metal and iron ore prices advanced after data showed manufacturing activity in top consumer China improved last month, while energy advanced 0.6%. The technology sector, which houses Europe's major chipmakers, jumped 0.7%, in line with their rising Wall Street counterparts. Keeping a lid on gains, telecoms and insurers fell 0.4% each. Volumes are expected to be light as traders return from an extended Christmas break with only a few trading days left in 2023. Bayer rose 1.7% after the German drugs-to-pesticides group said it has won a trial in a lawsuit brought by a California man who said he developed cancer from exposure to its Roundup weedkiller.

By Brendan Pierson

By Brendan Pierson

By Pablo Mayo Cerqueiro

Harry Kane made history during Bayern Munich’s triumphant 3-0 victory against Stuttgart on Sunday. The 30-year-old football sensation showcased his prowess by netting two goals, catapulting him into a new record as the fastest player to reach 20 Bundesliga goals. Kane's feat in just 14 games remarkably surpassed Uwe Seeler’s previous record by a staggering seven matches. Even Erling Haaland, the standout from Manchester City's ranks during his Borussia Dortmund stint, took 22 games to achieve the same milestone. Despite his incredible personal achievement, Kane humbly redirected the spotlight, praising the team's collective effort. «That was probably the best performance of the season,» he remarked about Bayern's exceptional win. Emphasizing the importance of the entire squad, he acknowledged, «We need the entire squad. Overall it was a very good performance today. We can be proud of that.»

Investing.com — European stock markets edged higher Tuesday, with investors awaiting the release of the latest eurozone inflation data as they start unwinding before the Christmas holidays. 

By Clark Mindock

Abhay Agarwal, Founder & Fund Manager, Piper Serica, says “we are seeing a lot of investors both in India and internationally under allocated on the risk assets, They are actually “desperately” looking to put on positions, get to a fair level of allocations. That is why we are seeing in the markets that anybody who did the hard work, stayed invested, used the downturn in the market to deploy capital, is finally getting rewarded. So it is a great reminder from the markets for all investors.” What a week has it been for a very long time. We have been spoiled by such massive gains in such a short period of time. This kind of a market makes all of us feel that we are great stock pickers and great participants in the market, does it not? We have been investing for 30 years and I am again reminded that long-term investors should learn to ignore the general market perspectives and market wisdom because not much ago, there was a lot of caution, lot of worry about the markets Michael Burry was putting on a big short and people said look, he is a very smart guy who made billions shorting the market. Crude prices had gone up and there was a worry that the Fed will increase rates and a lot of investors got under allocated to the markets at that point of time.

By David Carnevali

BERLIN—Bayer Chief Executive Bill Anderson said the company would bounce back quickly from a recent spate of bad news, and warned that a breakup of the pharmaceutical and agricultural company was no universal cure for its ailments. A stream of negative news has rekindled calls from investors for Bayer to unlock value by spinning off its units into separate businesses. But in an interview with The Wall Street Journal this week, Anderson said the company couldn’t be distracted from the tough restructuring to fix the businesses.

The dollar extended a decline, with a gauge of greenback strength hitting its lowest level since August, amid speculation the Federal Reserve is nearing the end of its rate-hike cycle.

Want to get this in your inbox at lunchtime every weekday? Financial Review subscribers can sign up for The Brief newsletter here. Plus start your day with our Before the Bell newsletter and read a full wrap of the day’s news in Market Wrap.

Instagram Reels dominates beauty purchases in India Moreover, critical sections of the country’s public transport system were rendered inoperable. The outage also led to the failure of hundreds of emergency calls intended for police, ambulances, and firefighters. Following her appearance last week in a parliamentary inquiry investigating the outage, Bayer Rosmarin faced escalating pressure to quit her position.